F 0755
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Some
Provide pharmaceutical services to meet the needs of each resident and employ or obtain the services of a
licensed pharmacist.
Based on medical record review, staff interview interview, and policy review, the facility failed to ensure
medications were given per physician orders upon admission. This affected five (#29, #32, #110, #111, and
#112) of five residents reviewed for medications. The facility census was 93.
Findings include:
1. Review of the medical record for Resident #29 revealed an admission date of 12/15/23. Diagnoses
included sepsis, chronic obstructive pulmonary disease, hypertension, heart failure, coronary artery
disease, and depression.
Review of December 2023 physician orders for Resident #29 revealed an order for the cholesterol lowering
medication Lipitor 10 milligrams (mg) at bedtime, the sleep aid melatonin three (3) mg at bedtime, the
antidepressant trazodone 50 mg at bedtime, the antibiotic cefazolin 1-4 grams intravenously (IV) in 50
milliliters (ml) three times daily, and the antihistamine meclizine 25 mg three times daily.
Review of the medication administration record (MAR) for December 2023 revealed on 12/15/23 Resident
#29 did not receive Lipitor 10 mg, melatonin 3 mg, and trazodone 50 mg at bedtime. Resident #29 also did
not receive cefazolin IV at 9:00 A.M. on 12/16/23. Resident #29 did not receive meclizine 25 mg at 9:00
A.M. on 12/18/23, 12/19/23, and 12/20/23, at 1:00 P.M. on 12/18/23 and 12/20/23, and at 5:00 P.M. on
12/18/23, 12/19/23, and 12/20/23.
2. Review of the medical record for Resident #32 revealed an admission date of 12/18/23. Diagnoses
included atherosclerotic heart disease of native coronary artery, type two diabetes, persistent atrial
fibrillation, coronary angioplasty, hallucinations, depression, hypertension, and chronic kidney disease.
Review of December 2023 physician orders for Resident #32 revealed an order for the antipsychotic
risperidone one (1) mg at bedtime, the anticoagulant Eliquis five (5) mg twice daily, and the hypertension
medication Cardizem extended release 240 mg daily in the morning.
Review of the MAR for December 2023 revealed Resident #32 did not receive risperidone 1 mg and Eliquis
5 mg at bedtime on 12/18/23 and cardizem extended release 240 mg the morning of 12/19/23.
3. Review of the medical record for Resident #110 revealed an admission date of 11/18/23. Diagnoses
included cardiac arrest, end stage renal disease, type two diabetes, chronic obstructive pulmonary disease
(COPD), anxiety, syncope and collapse, hypertension, heart failure, and atherosclerotic
(continued on next page)
Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other
safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the
date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date
these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER
REPRESENTATIVE'S SIGNATURE
TITLE
(X6) DATE
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Facility ID:
If continuation sheet
Page 1 of 3
Event ID:
365829
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
365829
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
12/21/2023
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Villa Springfield Rehabilitation and Healthcare Ce
701 Villa Road
Springfield, OH 45503
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0755
heart disease of coronary artery. The resident was discharged on 11/28/23.
Level of Harm - Minimal harm
or potential for actual harm
Review of November 2023 physician orders for Resident #110 revealed orders for Lipitor 80 mg at bedtime,
the antidepressant sertraline 50 mg at bedtime, the medications to treat COPD including Stiolto Respimat
inhalation 2.5-2.5 micrograms (mcg/act) two (2) puffs orally twice daily and budesonide-formoterol fumarate
inhalation 80-4.5 mcg/act 2 puffs orally twice daily, the nitrate medication isosorbide mononitrate extended
release (ER) 30 mg twice daily, and the diuretic metolazone 5 mg twice daily.
Residents Affected - Some
Review of the November 2023 MAR for Resident #110 revealed on 11/18/23 at bedtime the resident did not
receive Lipitor 80 mg, sertraline 50 mg, Stiolto Respimat inhalation, budesonide-formoterol fumarate,
isosorbide ER 30 mg, and metolazone 5 mg. Resident #110 also did not receive budesonide-formoterol
fumarate in the morning on 11/19/23.
4. Review of the medical record for Resident #111 revealed an admission date of 10/12/23. Diagnoses
included sepsis, chronic respiratory failure, type two diabetes, chronic obstructive pulmonary disease, acute
kidney failure, depression, heart failure, hypertension, and coronary artery disease. The resident was
discharged on 11/20/23.
Review of October 2023 physician orders for Resident #111 revealed orders for Lantus solostar insulin 100
units/ml inject 32 units subcutaneously (SQ) at bedtime, the nerve pain medication pregabalin 25 mg daily,
the medication to treat COPD fluticasone-salmeterol inhalation 250-50 mcg/act 1 puff twice daily, and the
pain medication oxycontin ER abuse deterrent 20 mg every 12 hours until 11/11/23.
Review of the October 2023 MAR for Resident #111 revealed on 10/13/23 and 10/14/23 the resident did
not receive Lantus solostar 32 units SQ at bedtime. On 10/13/23, Resident #111 did not receive
fluticasone-salmeterol at 6:00 A.M. On 10/12/23 at 6:00 P.M. and 10/13/23 at 6:00 A.M., the resident did not
receive oxycontin ER abuse deterrent 20 mg. Also, on 10/13/23, the resident did not receive pregabalin 25
mg in the morning.
5. Review of the medical record for Resident #112 revealed an admission date of 11/07/23. Diagnoses
included COPD, chronic respiratory failure, type two diabetes, glaucoma, depression, anemia,
hypertension, seizures, congestive heart failure, and atherosclerotic heart disease of native coronary
artery. The resident was discharged on 12/06/23.
Review of November 2023 physician orders for Resident #112 revealed orders for the antihistamine
azelastine nasal solution 0.1 percent (%) both nostrils twice daily, the medication to treat COPD
budesonide-formoterol fumerate inhalation aerosol 160-4.5 mcg/act 2 puffs twice daily, the medication for
glaucoma dorzolamide solution 2% one drop in both eyes twice daily, Farxiga 10 mg daily for diabetes,
glucophage 1000 mg twice daily for diabetes, insulin glargine solostar pen 100 units/ml inject 35 units SQ
at bedtime, the cholesterol medications fenofibrate 160 mg at bedtime and rosuvastatin 40 mg at bedtime,
and venlafaxine ER 75 mg daily for depression.
Review of the November 2023 MAR for Resident #112 revealed on 11/07/23 the resident did not receive
insulin glargine 35 units SQ, fenofibrate 160 mg, rosuvastatin 40 mg, venlafaxine ER 75 mg,
budesonide-formoterol fumerate inhalation, dorzolamid solution 2%, glucophage 1000 mg, and azelastine
nasal solution at bedtime. Also, Resident #112 did not receive Farxiga 10 mg in the morning on 11/08/23.
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
365829
If continuation sheet
Page 2 of 3
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
365829
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
12/21/2023
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Villa Springfield Rehabilitation and Healthcare Ce
701 Villa Road
Springfield, OH 45503
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0755
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Some
Interview on 12/21/22 at 9:30 A.M. with the Director of Nursing (DON) verified Resident #29, Resident #32,
Resident #110, Resident #111, and Resident #112 did not receive medications as ordered, from the
examples above, on the evening each resident admitted to the facility. The DON stated she was educating
all nurses on pulling medications from the Omnicell (emergency medication back-up system) or notifying
the physician to ensure medications can be held and started the next day when the medications were
available from the pharmacy.
Review of an undated policy titled, Administering Medications, revealed medications must be administered
in accordance with the orders, including any required timeframes.
This deficiency represents non-compliance investigated under Complaint Number OH00148733.
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
365829
If continuation sheet
Page 3 of 3